
A long-held misconception that data generated in non-Caucasian populations has limited relevance for Caucasian markets continues to influence study protocol design despite the growing ethnic diversity of Western markets. However, trials designed around mechanism-driven end points do translate across populations, meaning that researchers can reliably study non-Caucasian populations, reducing cost and operational complexity of trials.





























